Cox Aaron 4
4 · Horizon Therapeutics Public Ltd Co · Filed Jan 4, 2023
Insider Transaction Report
Form 4
Cox Aaron
EVP, Chief Financial Officer
Transactions
- Exercise/Conversion
Ordinary Shares
2022-12-30+64,906→ 65,183 total - Tax Payment
Ordinary Shares
2022-12-30$113.80/sh−28,758$3,272,660→ 36,425 total - Exercise/Conversion
Performance Restricted Stock Units (PSU)
2022-12-30−5,806→ 0 total→ Ordinary Shares (5,806 underlying) - Exercise/Conversion
Performance Restricted Stock Units (PSU)
2022-12-30−1,573→ 0 total→ Ordinary Shares (1,573 underlying) - Exercise/Conversion
Performance Restricted Stock Units (PSU)
2022-12-30−17,416→ 0 total→ Ordinary Shares (17,416 underlying) - Exercise/Conversion
Performance Restricted Stock Units (PSU)
2022-12-30−3,868→ 0 total→ Ordinary Shares (3,868 underlying) - Exercise/Conversion
Performance Restricted Stock Units (PSU)
2022-12-30−9,318→ 4,654 total→ Ordinary Shares (9,318 underlying) - Exercise/Conversion
Restricted Stock Units (RSU)
2022-12-30−9,676→ 0 total→ Ordinary Shares (9,676 underlying) - Exercise/Conversion
Restricted Stock Units (RSU)
2022-12-30−7,935→ 15,870 total→ Ordinary Shares (7,935 underlying) - Exercise/Conversion
Restricted Stock Units (RSU)
2022-12-30−9,314→ 9,314 total→ Ordinary Shares (9,314 underlying)
Footnotes (4)
- [F1]Each PSU/RSU represents a contingent right to receive one ordinary share of the Issuer.
- [F2]The final tranche of ordinary shares subject to the PSU/RSU vested on December 30, 2022.
- [F3]The remaining ordinary shares subject to the PSU/RSU vest on January 5, 2024.
- [F4]The remaining ordinary shares subject to the RSU vest ratably on January 5, 2024 and January 5, 2025.